{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:10:51Z","timestamp":1791411051327,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1053\/j.ackd.2014.01.003","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T23:01:23Z","timestamp":1393887683000},"page":"159-165","source":"Crossref","is-referenced-by-count":9,"title":["Sequential RAAS Blockade: Is It Worth the Risk?"],"prefix":"10.1053","volume":"21","author":[{"given":"Frederik","family":"Persson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2014.01.003_bib1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/bmj.293.6545.467","article-title":"Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy","volume":"293","author":"Hommel","year":"1986","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2014.01.003_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","article-title":"Renal protective effect of enalapril in diabetic nephropathy","volume":"304","author":"Bj\u00f6rck","year":"1992","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2014.01.003_bib3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib4","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 Diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.003_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials","volume":"151","author":"Bilous","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.003_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib13","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2014.01.003_bib14","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2014.01.003_bib15","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.003_bib16","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.003_bib17","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(08)60681-9","article-title":"The COOPERATE trial: a letter of concern","volume":"371","author":"Kunz","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.003_bib18","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2014.01.003_bib19","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.003_bib20","first-page":"151","article-title":"Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy","volume":"51","author":"Tan","year":"2010","journal-title":"Singapore Med J"},{"key":"10.1053\/j.ackd.2014.01.003_bib21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.ki.5002455","article-title":"Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial","volume":"72","author":"Bakris","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.003_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","article-title":"Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial","volume":"61","author":"Fernandez Juarez","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2014.01.003_bib23","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.003_bib24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2014.01.003_bib25","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.003_bib26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.003_bib27","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ndt\/gfp547","article-title":"Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease","volume":"25","author":"Frimodt-Moller","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2014.01.003_bib28","doi-asserted-by":"crossref","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","article-title":"Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study","volume":"6","author":"Boesby","year":"2011","journal-title":"PLoS One"},{"key":"10.1053\/j.ackd.2014.01.003_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.ackd.2014.01.003_bib30","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1053\/j.ackd.2014.01.003_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.003_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jash.2011.12.002","article-title":"Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with Stage 2 hypertension","volume":"6","author":"Ferdinand","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"10.1053\/j.ackd.2014.01.003_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jch.12032","article-title":"Randomized study of antihypertensive efficacy and safety of combination aliskiren\/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus","volume":"15","author":"Bakris","year":"2013","journal-title":"J Clin Hypertens"},{"key":"10.1053\/j.ackd.2014.01.003_bib34","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","article-title":"Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria","volume":"32","author":"Persson","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2014.01.003_bib35","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.07590810","article-title":"Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy","volume":"6","author":"Persson","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.003_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1470320311434818","article-title":"Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)","volume":"13","author":"Parving","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1053\/j.ackd.2014.01.003_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0140-6736(91)91043-T","article-title":"Chronic renal failure: management","volume":"338","author":"Klahr","year":"1991","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.003_bib39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the astronaut randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2014.01.003_bib40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2013.277169","article-title":"Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial","volume":"310","author":"Nicholls","year":"2013","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2014.01.003_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib42","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2014.01.003_bib43","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1136\/bmj.e42","article-title":"The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis","volume":"344","author":"Harel","year":"2012","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2014.01.003_bib44","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ki.2011.228","article-title":"Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients","volume":"80","author":"Chan","year":"2011","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.003_bib45","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/HJH.0b013e32835bf7b0","article-title":"Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial","volume":"31","author":"Mann","year":"2013","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2014.01.003_bib47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.003_bib48","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/HJH.0b013e32834f6e00","article-title":"Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?","volume":"30","author":"Volpe","year":"2012","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2014.01.003_bib49","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2014.01.003_bib50","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1470320312455271","article-title":"Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study","volume":"13","author":"de Boer","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1053\/j.ackd.2014.01.003_bib52","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.003_bib53","first-page":"646","article-title":"Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial","volume":"20","author":"Maione","year":"2007","journal-title":"J Nephrol"},{"key":"10.1053\/j.ackd.2014.01.003_bib54","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s00125-010-1789-6","article-title":"Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial","volume":"53","author":"Persson","year":"2010","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2014.01.003_bib55","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.003_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/HJH.0b013e328332bd61","article-title":"Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria","volume":"28","author":"Weir","year":"2010","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2014.01.003_bib57","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","article-title":"Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study","volume":"16","author":"Schmieder","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.003_bib58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"Supramaximal dose of candesartan in proteinuric renal disease","volume":"20","author":"Burgess","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.003_bib59","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/ndt\/17.8.1413","article-title":"Optimal dose of losartan for renoprotection in diabetic nephropathy","volume":"17","author":"Andersen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2014.01.003_bib60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00125-008-1184-8","article-title":"Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial","volume":"52","author":"Schjoedt","year":"2009","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2014.01.003_bib61","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514000068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514000068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T03:25:36Z","timestamp":1538796336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559514000068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1548559514000068"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2014.01.003","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}